IRIS PubliCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.313
NA - Nord America 2.308
AS - Asia 538
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
Totale 5.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.298
DE - Germania 935
SE - Svezia 443
CN - Cina 301
UA - Ucraina 236
IT - Italia 184
IE - Irlanda 126
FR - Francia 124
SG - Singapore 112
GB - Regno Unito 91
IN - India 67
FI - Finlandia 52
PL - Polonia 32
RU - Federazione Russa 32
TR - Turchia 27
BE - Belgio 20
IR - Iran 13
CA - Canada 8
NL - Olanda 8
CI - Costa d'Avorio 7
JP - Giappone 7
HK - Hong Kong 6
CH - Svizzera 4
CZ - Repubblica Ceca 4
ES - Italia 4
PT - Portogallo 4
BG - Bulgaria 3
GR - Grecia 3
HU - Ungheria 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
BZ - Belize 2
PH - Filippine 2
TW - Taiwan 2
AL - Albania 1
DK - Danimarca 1
EU - Europa 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
TN - Tunisia 1
VE - Venezuela 1
VN - Vietnam 1
Totale 5.174
Salva come PNG Salva come JPEG
Città #
Chandler 554
Ashburn 178
Jacksonville 167
Dublin 123
San Mateo 122
Dearborn 107
Ann Arbor 101
New York 89
Singapore 74
Nanjing 71
Wilmington 62
Cattolica 59
Nürnberg 59
Boston 49
Milan 41
Munich 41
Bremen 34
Houston 34
Princeton 34
Lawrence 33
Beijing 32
Izmir 27
Moscow 26
Los Angeles 25
Marseille 24
Lancaster 22
Fairfield 21
Kraków 21
Nanchang 20
Seattle 19
Woodbridge 19
Brussels 18
Redwood City 18
Shenyang 17
Hangzhou 15
Augusta 14
Boardman 14
Changsha 14
Leawood 13
Mountain View 12
Hebei 11
Jiaxing 11
Warsaw 11
Kunming 10
Tianjin 10
Detroit 9
Norwalk 9
Pune 9
Redmond 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Helsinki 8
Shanghai 8
Abidjan 7
Andover 7
Cagliari 7
Guangzhou 7
University Park 7
Fremont 6
San Jose 6
Washington 6
Hefei 5
Indiana 5
Jinan 5
Rome 5
Sacramento 5
Hong Kong 4
Kish 4
Millbury 4
Toronto 4
Bengaluru 3
Brno 3
Cambridge 3
Edinburgh 3
Lanzhou 3
London 3
San Diego 3
Simi Valley 3
Sofia 3
Tokyo 3
A Coruña 2
Amsterdam 2
Belize City 2
Berlin 2
Bologna 2
Budapest 2
Central 2
Changchun 2
Chicago 2
Chiswick 2
Corsico 2
Gunzenhausen 2
Henderson 2
Lappeenranta 2
Las Vegas 2
Lille 2
Monmouth Junction 2
Montreal 2
Mumbai 2
Totale 2.715
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 315
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 150
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 141
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 140
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 133
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 133
Early atherosclerosis in patients with inflammatory bowel disease. 131
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 130
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 127
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 120
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 118
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 117
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 110
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 110
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 104
Ileal Crohn's disease: CEUS determination of activity 101
Use of infliximab in particular clinical settings: management based on current evidence. 95
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 95
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 95
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 95
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 94
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 89
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 88
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 87
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 85
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 82
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 81
Management of perianal fistulas in Crohn's disease: an up-to-date review 72
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 72
Mucosal healing in ulcerative colitis: surveillance or colectomy? 68
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 68
AID in aging and autoimmune diseases 67
Adalimumab in active ulcerative colitis: a "real-life" observational study 64
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 63
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 63
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 63
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 61
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 59
Neuropeptide Y plasma levels and immunological changes during academic stress 55
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 55
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 54
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 52
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 52
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 52
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 52
[Soluble factors with immunosuppressive activity in human neoplasms] 50
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 50
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 49
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 49
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 48
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 48
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 47
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 47
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 47
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 44
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 40
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 40
Watery stools and metabolic acidosis 39
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 39
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 37
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 36
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 36
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 36
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 36
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 35
Linking estrogen receptor β expression with inflammatory bowel disease activity 35
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 31
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 21
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 16
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 12
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 10
Small bowel diseases 4
Small bowel diseases 3
Totale 5.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.867
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.867
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020571 0 0 66 27 52 109 62 31 55 23 102 44
2020/2021480 21 49 15 56 59 11 44 17 60 17 117 14
2021/2022646 55 45 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/202578 23 42 13 0 0 0 0 0 0 0 0 0
Totale 5.243